Extractables and Leachables Testing: Key Risk Checks

Extractables and leachables testing is a critical risk-control checkpoint for quality and safety teams managing single-use plastics, sterile packaging, and bioprocess consumables. As polymer materials contact high-value biologics, reagents, or medical devices, even trace chemical migrants can affect product purity, patient safety, and regulatory approval. This article outlines the key risk checks QC and safety managers should prioritize to strengthen validation, supplier qualification, and contamination control.

For laboratories, IVD kit manufacturers, sterile packaging suppliers, and biologics producers, the challenge is not only detecting unknown chemicals. The larger task is building a defensible, risk-based control system that connects material selection, supplier evidence, process exposure, toxicological review, and change management.

Why Extractables and Leachables Testing Matters in Life Science Consumables

Extractables and leachables testing is essential because polymers are not inert in every use condition. Plasticizers, antioxidants, slip agents, oligomers, curing residues, colorants, adhesives, and sterilization byproducts may migrate under heat, solvent exposure, pressure, or long storage.

In a typical bioprocess, a single product stream may contact 5–20 disposable components, including bags, tubing, filters, connectors, sampling bottles, and chromatography-related assemblies. Each contact point adds a possible chemical contribution.

Extractables versus leachables

Extractables are compounds released under exaggerated laboratory conditions, often using aggressive solvents, elevated temperatures, or extended extraction times. They show the potential chemical profile of a material.

Leachables are compounds that actually migrate into the drug product, reagent, culture medium, diagnostic sample, or medical device environment during intended use. They are usually more relevant to patient or assay risk.

High-risk contact scenarios

QC teams should prioritize extractables and leachables testing when materials contact aqueous buffers, organic modifiers, protein solutions, serum-free media, high-salt formulations, or lipid-containing matrices for more than several hours.

Sterilization also changes the risk picture. Gamma irradiation, electron beam, steam, and ethylene oxide may create or increase compounds that were not significant in the unsterilized material.

• Single-use bioprocess bags used for 24–72 hours of storage or mixing.
• Pipette tips and plates used in ultra-low-volume analytical workflows, including 10μL transfers.
• Sterile barrier packaging exposed to EO sterilization and long-distance shipping.
• IVD kit housings, reagent reservoirs, seals, and lyophilized reagent contact surfaces.
• Chromatography consumables where resin slurry, buffers, and storage agents interact with polymers.

Key Risk Checks Before Launching a Study

A strong study begins before the laboratory receives samples. Quality and safety managers need to define the component, intended use, contact duration, temperature range, solvent compatibility, sterilization method, and patient exposure route.

For many consumables, a practical risk assessment uses 3 tiers: low-contact screening, moderate-risk targeted evaluation, and full extractables and leachables testing for critical or long-duration applications.

Material and formulation review

The first check is material identity. Polypropylene, polyethylene, polycarbonate, cyclic olefin polymer, silicone, thermoplastic elastomer, nylon, and fluoropolymers have different additive packages and different extraction behaviors.

Suppliers should provide composition statements at an appropriate confidentiality level. At minimum, QC teams should request polymer family, colorant presence, processing aids, sterilization status, and any known substances of concern.

Use-condition mapping

The second check is real exposure. A pipette tip with seconds of contact is not equivalent to a 200 L single-use bag holding cell culture medium for 7 days.

Mapping should include worst-case but credible conditions. Useful inputs include pH 2–12, temperatures from 2°C to 40°C, contact times from minutes to months, and surface-area-to-volume ratios.

The table below summarizes how quality teams can classify common LSRS-related consumables before selecting a study depth for extractables and leachables testing.

The key conclusion is that exposure context drives study design. The highest-risk item is not always the largest component, but the one combining long contact, sensitive product chemistry, and limited downstream clearance.

Analytical uncertainty and reporting thresholds

Risk checks should also define reporting thresholds early. Many programs use analytical evaluation thresholds, identification thresholds, and safety concern thresholds to decide which peaks need structural identification.

For complex matrices, QC teams should expect orthogonal methods. GC-MS, LC-MS, ICP-MS, TOC, pH, conductivity, and non-volatile residue testing often reveal different parts of the chemical profile.

Designing a Defensible Extractables Study

Extractables studies are most useful when they are scientifically aggressive but still relevant. Overly mild studies miss potential hazards, while unrealistic extraction conditions can create artifacts that complicate decision-making.

A well-structured extractables and leachables testing plan usually defines 4 elements: extraction media, temperature, contact time, and analytical techniques. These choices should be justified in the protocol.

Solvent selection

Common extraction media include water, acidic solution, alkaline solution, salt solution, alcohol-water mixtures, and non-polar solvents. Selection should reflect both product chemistry and exaggerated extraction needs.

For bioprocess consumables, aqueous buffers and alcohol-water mixtures are frequently relevant. For sterile packaging adhesives or labels, semi-polar and non-polar solvents may be needed to capture hydrophobic migrants.

Temperature and duration

Typical accelerated extraction conditions may use 40°C, 50°C, or 70°C for 24–72 hours, depending on material stability. Steam-sterilized or heat-exposed components may justify different profiles.

Quality teams should avoid conditions that melt, crack, oxidize, or chemically destroy the material in ways unrelated to actual use. Visible deformation should be documented and assessed.

Analytical coverage checklist

1. Volatile and semi-volatile organics by GC-MS.
2. Non-volatile and polar compounds by LC-MS.
3. Elemental impurities and catalysts by ICP-MS.
4. General chemical indicators such as TOC, pH, conductivity, and residue.
5. Targeted assays for known additives, antioxidants, or sterilant residues.

For high-value biologics and gene therapy workflows, unknown peak investigation is often as important as targeted screening. A defensible report should explain identification confidence levels and remaining uncertainty.

Leachables Testing for Real-World Product Safety

Leachables testing translates potential risk into actual use risk. It examines whether compounds migrate into the product under normal storage, processing, shipping, or clinical-use conditions.

This part of extractables and leachables testing is especially important for final drug containers, long-term reagent storage, IVD calibrators, culture media bottles, and sterile device packaging.

Matrix interference and functional impact

Biological matrices are chemically complex. Proteins, surfactants, salts, buffers, vitamins, and preservatives can suppress ionization, mask peaks, or react with migrants during analysis.

For cell culture media, a leachable may not create obvious toxicity but can reduce CHO cell productivity by changing growth kinetics. Even a 5–10% yield shift may matter at scale.

For IVD reagents, low-level migrants can interfere with antibody binding, enzyme activity, chemiluminescent signals, or fluorescent microspheres. Functional assay confirmation should accompany chemical testing where performance is critical.

Toxicological assessment

Detected leachables require toxicological review based on exposure route, dose, duration, patient population, and compound class. The same concentration may carry different meaning in diagnostics, implants, or parenteral drugs.

QC and safety managers should ask whether the report includes permitted daily exposure logic, genotoxic impurity considerations, and uncertainty factors for unidentified or tentatively identified compounds.

When to repeat leachables testing

• A polymer grade, colorant, adhesive, resin, or film supplier changes.
• Sterilization dose, EO cycle, or irradiation site is modified.
• Product contact time increases from short use to long storage.
• A process temperature rises by 10°C or more.
• Unexpected assay drift, cell growth change, or impurity trend appears.

Supplier Qualification and Documentation Checks

For procurement and quality teams, supplier qualification is a core part of chemical safety. A low-cost consumable is not economical if missing data delays validation by 8–12 weeks.

Extractables and leachables testing should be supported by controlled documentation, not treated as a one-time certificate. Evidence must remain valid across batches, sites, raw materials, and sterilization configurations.

Documents to request during technical evaluation

Before approving a supplier for single-use plastics, sterile packaging, or bioprocess accessories, teams should request a documentation package that supports both quality release and regulatory filing needs.

This documentation review helps distinguish technically mature suppliers from those offering only basic certificates. It also supports multi-supplier strategies without compromising chemical safety standards.

Change control as a contamination barrier

Many failures occur after a quiet change: a new resin source, a modified mold release agent, a different irradiation dose, or an adhesive reformulation in sterile packaging.

A practical change control agreement should define at least 5 notification categories: raw material, formulation, manufacturing site, sterilization process, and packaging configuration.

Implementation Workflow for QC and Safety Teams

A repeatable workflow turns extractables and leachables testing from a reactive project into a preventive quality system. The goal is to reduce surprises during scale-up, audit, or regulatory review.

For most organizations, a 6-step workflow is sufficient to cover risk classification, supplier review, protocol design, analytical execution, toxicology, and ongoing monitoring.

Six practical steps

1. List all product-contact materials and assign owner responsibility.
2. Rank components by contact time, temperature, fluid type, and clinical relevance.
3. Collect supplier data, including prior extractables and leachables testing reports.
4. Design a protocol with justified solvents, methods, and thresholds.
5. Review analytical findings with toxicology and process experts.
6. Link results to change control, batch release, and periodic requalification.

Common mistakes to avoid

One common mistake is relying on generic vendor data without checking whether the tested article matches the purchased configuration, sterilization state, thickness, color, or contact surface.

Another mistake is ignoring functional risk. A leachable below a toxicological threshold may still affect protein binding, chromatography performance, cell viability, or diagnostic signal stability.

Practical acceptance logic

Acceptance should not rely on a single pass-or-fail number. It should combine chemical identification, concentration, exposure estimate, toxicological margin, product quality impact, and process clearance.

For critical consumables, many teams require cross-functional approval from quality, safety, process development, analytical development, and procurement before adding the material to an approved supplier list.

How LSRS Supports Better Risk Decisions

LSRS focuses on the consumables that keep life science pipelines running: laboratory single-use plastics, cell culture media, chromatography purification media, IVD diagnostic kits, and medical-grade sterile packaging.

For QC personnel and safety managers, the value of LSRS lies in connecting technical intelligence with purchasing decisions. Chemical cleanliness, batch consistency, supplier resilience, and cost performance must be reviewed together.

Decision support for supplier and product evaluation

The LSRS perspective emphasizes risk stitching across materials, processes, and end-use environments. This is especially useful when comparing 2–3 alternative suppliers for localization, dual sourcing, or COGs reduction.

Instead of asking only whether a consumable is cheaper, teams should ask whether it has adequate extractables and leachables testing evidence, stable manufacturing controls, and responsive change notification.

Questions to ask before approval

• Does the extractables profile cover the sterilized, final-use configuration?
• Are unknowns above the reporting threshold identified or scientifically justified?
• Does the leachables study reflect the product matrix and storage duration?
• Are EO residuals, irradiation byproducts, or adhesive migrants relevant?
• Can the supplier notify changes within a defined period, such as 30–90 days?
• Is there a clear plan for requalification after process or material changes?

These questions help quality teams move from certificate collection to evidence-based approval. They also reduce the risk of late-stage failures during validation, scale-up, or regulatory submission.

Risk-Control Takeaways for Quality and Safety Managers

Extractables and leachables testing is not a laboratory formality. It is a strategic checkpoint for protecting product purity, patient safety, assay reliability, and the credibility of supplier qualification.

The strongest programs combine material knowledge, realistic exposure mapping, orthogonal analytical methods, toxicological assessment, and disciplined change control. This approach is practical for both global suppliers and buyers.

For organizations managing single-use systems, sterile packaging, chromatography-related consumables, or IVD reagent components, early risk assessment can prevent costly redesigns and delayed approvals later.

LSRS helps quality, safety, and procurement teams evaluate consumable risks with a sharper technical lens and a clearer supplier strategy. To strengthen your validation roadmap, consult product details, compare supplier evidence, or contact us to get a tailored risk-control solution.